You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
|
|---|---|
| Published in |
BMC Cancer, February 2016
|
| DOI | 10.1186/s12885-016-2209-1 |
| Pubmed ID | |
| Authors |
Soojin Cha, Jeongeun Lee, Jong-Yeon Shin, Ji-Yeon Kim, Sung Hoon Sim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Se-Hoon Lee, Jong-Il Kim |
| Abstract |
Although adolescent and young adult (AYA) cancers are characterized by biological features and clinical outcomes distinct from those of other age groups, the molecular profile of AYA cancers has not been well defined. In this study, we analyzed cancer genomes from rare types of metastatic AYA cancers to identify driving and/or druggable genetic alterations. Prospectively collected AYA tumor samples from seven different patients were analyzed using three different genomics platforms (whole-exome sequencing, whole-transcriptome sequencing or OncoScan™). Using well-known bioinformatics tools (bwa, Picard, GATK, MuTect, and Somatic Indel Detector) and our annotation approach with open access databases (DAVID and DGIdb), we processed sequencing data and identified driving genetic alterations and their druggability. The mutation frequencies of AYA cancers were lower than those of other adult cancers (median = 0.56), except for a germ cell tumor with hypermutation. We identified patient-specific genetic alterations in candidate driving genes: RASA2 and NF1 (prostate cancer), TP53 and CDKN2C (olfactory neuroblastoma), FAT1, NOTCH1, and SMAD4 (head and neck cancer), KRAS (urachal carcinoma), EML4-ALK (lung cancer), and MDM2 and PTEN (liposarcoma). We then suggested potential drugs for each patient according to his or her altered genes and related pathways. By comparing candidate driving genes between AYA cancers and those from all age groups for the same type of cancer, we identified different driving genes in prostate cancer and a germ cell tumor in AYAs compared with all age groups, whereas three common alterations (TP53, FAT1, and NOTCH1) in head and neck cancer were identified in both groups. We identified the patient-specific genetic alterations and druggability of seven rare types of AYA cancers using three genomics platforms. Additionally, genetic alterations in cancers from AYA and those from all age groups varied by cancer type. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 20% |
| United States | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Czechia | 1 | 1% |
| Germany | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 69 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 21% |
| Student > Ph. D. Student | 9 | 12% |
| Researcher | 9 | 12% |
| Other | 4 | 5% |
| Professor > Associate Professor | 3 | 4% |
| Other | 12 | 16% |
| Unknown | 21 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 33% |
| Biochemistry, Genetics and Molecular Biology | 8 | 11% |
| Agricultural and Biological Sciences | 4 | 5% |
| Computer Science | 3 | 4% |
| Nursing and Health Professions | 2 | 3% |
| Other | 8 | 11% |
| Unknown | 24 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2016.
All research outputs
#13,203,183
of 23,613,071 outputs
Outputs from BMC Cancer
#2,772
of 8,487 outputs
Outputs of similar age
#133,343
of 298,930 outputs
Outputs of similar age from BMC Cancer
#49
of 177 outputs
Altmetric has tracked 23,613,071 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,487 research outputs from this source. They receive a mean Attention Score of 4.4. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,930 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 177 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.